Results Among 267 patients treated with afatinib financed as the first line of treatment, 76
(28.46%) deaths occurred. Median observation time was 12.8 months (95% CI: 11.2–13.9) …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …

Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the
preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung …

Objectives Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …

Abstract Background Tyrosine-kinase inhibitors (TKIs) have become the cornerstone
treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations …

Methods A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive
treated with gefitinib (n= 59), erlotinib (n= 22), and afatinib (n= 7) was performed in national …

Simple Summary Lung cancer is one of the most frequently diagnosed malignant diseases
in Poland. Presented real-world data might help in making a clinical decision on cancer …

Objectives First-line EGFR-TKIs has become established in EGFR mutation–positive
NSCLC. According to large scale meta-analysis, erlotinib and afatinib showed a non …

Therapy for advanced non-small cell lung cancer (NSCLC) is very complex clinical problem.
The optimal choice of therapy demands not only the analysis of data on clinical …

Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …